NCT00565097View on ClinicalTrials.gov

Lanreotide as Treatment of Polycystic Livers

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

October 31, 2007

Conditions
Polycystic Liver DiseaseHepatomegalyLiver DiseasesPolycystic Kidney, Autosomal Dominant
Interventions
DRUG

Placebo

DRUG

Lanreotide

Trial Locations (2)

Unknown

University Hospital Gasthuisberg, Leuven

Radboud University Medical Center, Nijmegen

Sponsors

Collaborators (1)

Ipsen
All Listed Sponsors
collaborator

Ipsen

INDUSTRY

lead

Radboud University Medical Center

OTHER